Select Medical Q4 2024 Earnings Report
Key Takeaways
Select Medical Holdings Corporation reported a 7.8% increase in revenue for Q4 2024, reaching $1.31 billion. However, the company posted a net loss from continuing operations of $10.5 million due to a one-time stock compensation acceleration of $45.9 million and a $17.9 million loss on early retirement of debt. Adjusted EPS increased by 50% to $0.18. Adjusted EBITDA rose 3.8% to $116.0 million.
Q4 revenue grew 7.8% YoY to $1.31 billion.
Loss from continuing operations was $10.5 million due to one-time expenses.
Adjusted EPS increased 50% YoY to $0.18.
Adjusted EBITDA rose 3.8% to $116.0 million.
Select Medical Revenue
Select Medical EPS
Select Medical Revenue by Segment
Forward Guidance
For 2025, Select Medical expects revenue between $5.4 billion and $5.6 billion, Adjusted EBITDA between $520 million and $540 million, and diluted EPS between $1.09 and $1.19.
Positive Outlook
- Revenue expected to grow to $5.4B - $5.6B in 2025.
- Adjusted EBITDA projected between $520M - $540M.
- EPS expected to rise between $1.09 - $1.19.
- Improved cost control measures expected to enhance margins.
- Expansion in rehabilitation and outpatient services planned.
Challenges Ahead
- Continued impact of labor cost inflation on margins.
- Higher interest expenses due to recent debt refinancing.
- Potential reimbursement pressures from government programs.
- Challenges in retaining and attracting qualified healthcare professionals.
- Macroeconomic uncertainties affecting patient volumes.